Our Mission

In 2023, the KDA awarded four grants and one fellowship. The total amount of the 2023 research grant awards were $437,000.00. This is the highest amount for any single year in KDA's history.

Avenue Therapeutics and AnnJi are excited to announce the first patient to be dosed in the clinical trial of AJ201. There are currently six AnnJi drug trial distribution sites. For more information about the drug and the distribution sites, click here.

Check out our KDA calendar for Kennedy's Disease events and local fundraisers.

The KD patient registry was developed jointly with Sanford Research, the NIH and the KDA. This registry will facilitate KD/SBMA research and will be used to invite patients for clinical trials. Most important, a robust registry will provide a roadmap for investigators and will help them develop improved treatments and potentially a cure for this debilitating rare disease. For more information and to register, click here.

Nido Biosciences announces the development of NIDO-361 and the Unexpected frequency of the pathogenic AR CAG repeat expansion in the general population. To view the latest Kennedy's Disease Research, click here.

The KDA will be developing a series of short (1-2 page) reference guides on different aspects of KD including symptoms and management approaches. These documents will provide information to patients as well as medical personnel who may not be familiar with KD. The KDA just finished the first 2 reference guides: "KD Diagnosis and DNA Testing" and "KD and Female Carriers". To access these guides, click here.